Non-peptide

Garetosmab

Also known as

REGN2477 · anti-activin A antibody · Pasatru · garetosmab-grts · COURAGE triplet antibody

Community talk. May contain inaccuracies. Not medical advice. Not a protocol. Not for human or animal use.

What it is

Activin A antibody	Garetosmab, or REGN2477, binds activin A. It is different from trevogrumab, which targets myostatin; the COURAGE combination blocked both signals.
Why biohackers discuss it	Interest centers on preserving muscle during weight loss and avoiding steroid drawbacks. Most discussion is about trials and hopes, rather than verified physique diaries.

Notes

A different antibody target. Garetosmab (REGN2477) is a manufactured protein binding activin A. Trevogrumab targets myostatin. COURAGE blocked both signals; a forum’s peptide label blurs two distinct drugs. ClinicalTrials.gov COURAGE NCT06299098 API (Official context · Accessed 2026-09-30) · Biohackers: These new drugs for myostatin inhibition are going to be a game changer (Community discussion · Accessed 2026-09-30)

Garetosmab is an antibody that blocks activin A. Biohackers discuss it alongside trevogrumab and semaglutide for preserving muscle during weight loss, with hopes of a steroid alternative. Those hopes mostly come from trial discussion, not verified physique diaries. Trial benefits had tolerability costs.

A possible alternative to steroid effects. Canadian Brawn posters sound excited about avoiding familiar steroid drawbacks, while recalling earlier myostatin ideas that fizzled. MESO contributors ask whether this is a breakthrough or another disappointment. These are expectations, not people reporting that Garetosmab improved their strength or appearance. Canadian Brawn: Regeneron Pharmaceuticals: Trevogrubab & Garetosmab (Community opinion · Accessed 2026-09-30) · MESO-Rx: Anyone heard of Trevogrumab and Garetosmab? (Community discussion · Accessed 2026-09-30)

Source context — ClinicalTrials.gov COURAGE NCT06299098 API: API read using urllib; confirms IV route and combination, but not a numeric dosing frequency. Monthly COURAGE calendar retained from frozen profile.dosing_ranges_reported[1], not claimed freshly confirmed by API.

Source context — Biohackers: These new drugs for myostatin inhibition are going to be a game changer: Discussion of primate results and human trial interpretation, not personal exposure. Claimed clinical-research credentials unverified. Collapsed replies not inspected; some commenters confuse species.

Source context — Canadian Brawn: Regeneron Pharmaceuticals: Trevogrubab & Garetosmab: Three short posts; low-side-effect expectation is speculation, and volunteering as 'the study' does not establish exposure.

Source context — MESO-Rx: Anyone heard of Trevogrumab and Garetosmab?: Anonymous opinions and recalled monkey numbers; intent to experiment is not a use report. Commercial forum environment. No source/purchase instructions reproduced.

What people notice

Personal outcomes	The inspected record provides no authenticated account of garetosmab improving a lifter's strength or appearance. Enthusiasm and intended experimentation are not treatment results.
Trial context	COURAGE's triplet reduced lean-mass loss during weight loss rather than eliminating it. That is different from growing new muscle in trained lifters.

Notes

No community physique dose range was established. The opened MESO and bodybuilding discussions contain interest and intended experimentation, not a documented Garetosmab amount, route and repeat schedule used by a reporter. Trial milligrams belong to the separately labeled context below; they are not a community regimen. MESO-Rx: Anyone heard of Trevogrumab and Garetosmab? (Community discussion · Accessed 2026-09-30) · Evolutionary: Myostatin Antagonist and Activin-A antagonist opinions (Community discussion · Accessed 2026-09-30)

No reliable day-by-day onset report. The inspected excitement concerns body-composition results, not an authenticated first-person Garetosmab timeline. There is no supported countdown to a pump, strength change or visible muscle gain. A scheduled scan measures an outcome at that visit; it does not date when someone first felt an effect.

Holding onto muscle while losing fat. The Biohackers opener imagines gains without lifting and possible help for age-related muscle loss. A reply stresses that the human combinations reduced lean-mass loss rather than eliminating it. Preserving tissue during a calorie deficit and growing new muscle in trained lifters are different questions. Biohackers: These new drugs for myostatin inhibition are going to be a game changer (Community discussion · Accessed 2026-09-30)

September 2025 COURAGE results. Garetosmab 10 mg/kg IV every four weeks joined semaglutide and higher-dose trevogrumab. At 26 weeks, lean mass fell 2.0% versus 6.5% on semaglutide, with greater fat loss. Scans excluded post-discontinuation observations. The next 26 weeks compared trevogrumab with placebo. Regeneron: complete 26-week COURAGE results (Official context · Accessed 2026-09-30) · ClinicalTrials.gov COURAGE NCT06299098 API (Official context · Accessed 2026-09-30)

Source context — Evolutionary: Myostatin Antagonist and Activin-A antagonist opinions: Sponsored steroid-forum environment; promotional signatures excluded. Monkey figures repeat video material and differ from MESO recollections; no independent human outcomes.

Source context — Regeneron: complete 26-week COURAGE results: Sponsor report; excludes post-discontinuation observations from efficacy estimate; multiplicity unadjusted. Combination cannot isolate one antibody. Same release family as investor/PDF mirrors.

Doses people talk about

Community amount	The opened physique discussions establish no personal garetosmab amount, route and repeat schedule.
COURAGE: trial amount	10 mg/kg IV every four weeks was combined with semaglutide and higher-dose trevogrumab. This is a trial arm, not a community regimen.
FOP: separate label context	The saved disease-specific label starts at 10 mg/kg IV every four weeks, with 3 mg/kg if not tolerated. It does not establish bodybuilding dosing.

Notes

FOP amounts and persistence are disease-specific. The label starts at 10 mg/kg IV every four weeks, reducing to 3 mg/kg if not tolerated. After repeated dosing, modeled median time to undetectable blood concentrations was about 24 and 17 weeks, respectively. Those are not half-lives, onset times or duration-of-benefit measurements. Pasatru prescribing information and Medication Guide, August 2026 (Official context · Accessed 2026-09-30)

Pasatru treats a separate bone-growth disease. Pasatru, or garetosmab-grts, is approved for adults with FOP, where bone forms outside the skeleton. It is an IV infusion product. That approval does not establish a bodybuilding benefit. Pasatru prescribing information and Medication Guide, August 2026 (Official context · Accessed 2026-09-30)

Source context — Pasatru prescribing information and Medication Guide, August 2026: FOP-specific label; not an obesity or physique regimen. Modeled time to undetectable concentration is not a half-life or felt-effect duration. Label source family includes FDA PDF and manufacturer mirrors.

Half-life, onset & duration

Felt onset	No reliable first-person onset timeline is established. A scheduled body scan does not date a first felt effect.
Felt duration	Benefit after one infusion, persistence after stopping and return to baseline remain unknown in the inspected physique record.
Half-life	No supported community human value is established. Monthly infusions, FLGR timing and modeled time until undetectable blood levels are not garetosmab half-lives.

Notes

Benefit after one infusion or after stopping is unknown. No verified physique diary in the inspected record establishes hours or weeks of benefit, persistence after withdrawal, or a return-to-baseline time. Lack of such a report also does not imply quick clearance; bodily persistence and felt benefit are different.

A community human half-life is unknown. The preserved comparison warns against importing FLGR albumin-binding numbers. The Peptide Critic thread explicitly contrasts FLGR with these antibodies; its nearby timing claims concern FLGR. A monthly infusion interval also does not mean half the antibody disappears in one month. Peptide Critic: Klotho / FLGR242 (albumin-bound new tech) (Community discussion · Accessed 2026-09-30)

Source context — Peptide Critic: Klotho / FLGR242 (albumin-bound new tech): Displayed body omits post dates. Promotional/product-cheatsheet language and commercial brand mentions present. Adjacent first-person reports are about FLGR, Klotho or retatrutide, not Garetosmab.

Cycles people discuss

Bodybuilding cycles	The threads do not supply a completed garetosmab course with follow-up, or a supported repeat-course interval or off-period.
Trial versus disease treatment	COURAGE assessed the weight-loss phase at 26 weeks. Chronic FOP treatment and FLGR vendor blocks are separate calendars.

Notes

No established bodybuilding cycle. The old discussion distinguishes the obesity-trial calendar from chronic FOP treatment and FLGR vendor blocks. The opened threads do not supply a completed Garetosmab course with outcomes and follow-up. No repeat-course interval or off-period can be inferred from their enthusiasm. Canadian Brawn: Regeneron Pharmaceuticals: Trevogrubab & Garetosmab (Community opinion · Accessed 2026-09-30)

FOP treatment: A chronic disease program cannot supply a 12-week bodybuilding cycle or an off-period. [trial]

Stacks

COURAGE triplet	Semaglutide plus trevogrumab plus garetosmab is a documented trial combination. Its results cannot isolate garetosmab's contribution.

Notes

+ Semaglutide + trevogrumab is the COURAGE triplet. [trial]

COURAGE benefit and tolerability. June 2025 interim discontinuations for adverse events were 28.3% with the triplet versus 4.6% with semaglutide alone. Two triplet participants died; Regeneron reported no identified causal association. Combination findings cannot isolate Garetosmab’s effects. Regeneron: interim COURAGE results (Official context · Accessed 2026-09-30)

Source context — Regeneron: interim COURAGE results: Interim analysis from same trial as September report, not independent corroboration; forum 28% claim traced here.

Watch for

Trial tolerability	In the interim report, adverse events led 28.3% of the three-drug group to stop treatment, versus 4.6% on semaglutide alone. Two people in the three-drug group died; the sponsor reported no identified causal association.
Disease-label warnings	The saved FOP label warns about fetal harm, serious skin infections and nosebleeds; contraception and avoiding breastfeeding extend six months after the last dose. Male fertility may be affected.
Unverified products	An online listing does not authenticate an antibody or its storage. The threads do not establish long-term safety in healthy lifters.

Notes

Pregnancy, infections and nosebleeds matter. The FOP label contraindicates pregnancy and warns of fetal harm, serious skin infections and nosebleeds. Contraception and avoidance of breastfeeding extend six months beyond the last dose. Male fertility may be affected; drug-interaction studies were not conducted. Pasatru prescribing information and Medication Guide, August 2026 (Official context · Accessed 2026-09-30)

A listing is not an authenticated antibody. MESO replies emphasize manufacturing and storage differences from hormones. Wanting to experiment, joking about being a study, or finding a name online does not verify identity, quality or an outcome. The inspected threads do not establish long-term safety in healthy lifters. MESO-Rx: Anyone heard of Trevogrumab and Garetosmab? (Community discussion · Accessed 2026-09-30)

Source context — Regeneron: interim COURAGE results: Interim analysis from same trial as September report, not independent corroboration; forum 28% claim traced here.

Full notes

What Garetosmab is

A different antibody target. Garetosmab (REGN2477) is a manufactured protein binding activin A. Trevogrumab targets myostatin. COURAGE blocked both signals; a forum’s peptide label blurs two distinct drugs. Official context Reddit r/Biohackers
Pasatru treats a separate bone-growth disease. Pasatru, or garetosmab-grts, is approved for adults with FOP, where bone forms outside the skeleton. It is an IV infusion product. That approval does not establish a bodybuilding benefit. Official context

Why people follow it

Holding onto muscle while losing fat. The Biohackers opener imagines gains without lifting and possible help for age-related muscle loss. A reply stresses that the human combinations reduced lean-mass loss rather than eliminating it. Preserving tissue during a calorie deficit and growing new muscle in trained lifters are different questions. Reddit r/Biohackers
A possible alternative to steroid effects. Canadian Brawn posters sound excited about avoiding familiar steroid drawbacks, while recalling earlier myostatin ideas that fizzled. MESO contributors ask whether this is a breakthrough or another disappointment. These are expectations, not people reporting that Garetosmab improved their strength or appearance. Canadian Brawn MESO-Rx

Doses people discuss

No community physique dose range was established. The opened MESO and bodybuilding discussions contain interest and intended experimentation, not a documented Garetosmab amount, route and repeat schedule used by a reporter. Trial milligrams belong to the separately labeled context below; they are not a community regimen. MESO-Rx Evolutionary.org

Half-life in community discussion

A community human half-life is unknown. The preserved comparison warns against importing FLGR albumin-binding numbers. The Peptide Critic thread explicitly contrasts FLGR with these antibodies; its nearby timing claims concern FLGR. A monthly infusion interval also does not mean half the antibody disappears in one month. Community Peptide Critic Community

When people notice a change

No reliable day-by-day onset report. The inspected excitement concerns body-composition results, not an authenticated first-person Garetosmab timeline. There is no supported countdown to a pump, strength change or visible muscle gain. A scheduled scan measures an outcome at that visit; it does not date when someone first felt an effect. Community

How long effects last

Benefit after one infusion or after stopping is unknown. No verified physique diary in the inspected record establishes hours or weeks of benefit, persistence after withdrawal, or a return-to-baseline time. Lack of such a report also does not imply quick clearance; bodily persistence and felt benefit are different. Community

Cycles and pauses people discuss

No established bodybuilding cycle. The old discussion distinguishes the obesity-trial calendar from chronic FOP treatment and FLGR vendor blocks. The opened threads do not supply a completed Garetosmab course with outcomes and follow-up. No repeat-course interval or off-period can be inferred from their enthusiasm. Community Canadian Brawn

What the enthusiasm can miss

COURAGE benefit and tolerability. June 2025 interim discontinuations for adverse events were 28.3% with the triplet versus 4.6% with semaglutide alone. Two triplet participants died; Regeneron reported no identified causal association. Combination findings cannot isolate Garetosmab’s effects. Official context
Pregnancy, infections and nosebleeds matter. The FOP label contraindicates pregnancy and warns of fetal harm, serious skin infections and nosebleeds. Contraception and avoidance of breastfeeding extend six months beyond the last dose. Male fertility may be affected; drug-interaction studies were not conducted. Official context
A listing is not an authenticated antibody. MESO replies emphasize manufacturing and storage differences from hormones. Wanting to experiment, joking about being a study, or finding a name online does not verify identity, quality or an outcome. The inspected threads do not establish long-term safety in healthy lifters. MESO-Rx

What the community disagrees about

More targeted does not settle safety. The Retatrutide opener claims freedom from steroid side effects; a reply explicitly pastes a ChatGPT safety answer. Another contributor highlights human discontinuations and deaths. A different member chooses to wait because they have not noticed muscle loss. That last account is a decision, not nonresponse after use. Reddit r/Retatrutide
Animal gain and human preservation get mixed together. Evolutionary posters circulate monkey fat-loss and muscle-gain figures, then ask for actual human results and antibody-only comparisons. The figures are animal findings repeated through a video, not gym transformations. Community questions about heart growth are hypotheses, not documented Garetosmab adverse-event diaries. Evolutionary.org
FLGR comparisons do not make the products interchangeable. The preserved skeptic argument uses COURAGE against claims that avoiding activin blockade is necessarily better. In Peptide Critic, a user asks how the antibodies differ from Klotho and follistatin; a reply calls them different conversations. Nearby FLGR gains, pauses and heart-scan reports cannot be transferred to Garetosmab. Community Peptide Critic Community

Separately labeled trial and label context

September 2025 COURAGE results. Garetosmab 10 mg/kg IV every four weeks joined semaglutide and higher-dose trevogrumab. At 26 weeks, lean mass fell 2.0% versus 6.5% on semaglutide, with greater fat loss. Scans excluded post-discontinuation observations. The next 26 weeks compared trevogrumab with placebo. Official context Official context
FOP amounts and persistence are disease-specific. The label starts at 10 mg/kg IV every four weeks, reducing to 3 mg/kg if not tolerated. After repeated dosing, modeled median time to undetectable blood concentrations was about 24 and 17 weeks, respectively. Those are not half-lives, onset times or duration-of-benefit measurements. Official context